mRNA |
canertinib |
CTRPv2 |
pan-cancer |
AAC |
-0.096 |
0.007 |
mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.007 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.007 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.093 |
0.008 |
mRNA |
Bosutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.009 |
mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.086 |
0.009 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.01 |
mRNA |
PF-573228 |
CTRPv2 |
pan-cancer |
AAC |
-0.086 |
0.01 |
mRNA |
OSI-027 |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.01 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.01 |